Open AccessLong-term Clinical Effectiveness of Ustekinumab in Patients with Crohn’s Disease Who Failed Biologic Therapies: A National Cohort Study
Author(s) -
Claire Liefferinckx,
Bram Verstockt,
Ann Gils,
Maja Noman,
Catherine Van Kemseke,
Elisabeth Macken,
Martine De Vos,
Wouter Van Moerkercke,
JeanFrançois Rahier,
Peter Bossuyt,
Joris Dutré,
Evelien Humblet,
Dirk Staessen,
Harald Peeters,
Philippe Van Hootegem,
Édouard Louis,
Denis Franchimont,
Filip Baert,
Séverine Vermeire
Publication year - 2019
Publication title -
journal of crohn s and colitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.277
H-Index - 80
eISSN - 1876-4479
pISSN - 1873-9946
DOI - 10.1093/ecco-jcc/jjz080
Subject(s) - medicine , ustekinumab , adverse effect , crohn's disease , concomitant , vedolizumab , cohort , adalimumab , retrospective cohort study , ankylosing spondylitis , gastroenterology , surgery , disease
Ustekinumab [UST] was recently approved in Europe for the treatment of moderate to severe Crohn's disease [CD]. Long-term real-world data are currently scarce for CD patients previously exposed to several biologics.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom